Our Autologous Approach
Our lead autologous product, TAC101-Claudin 18.2, is designed to target Claudin 18.2-expressing tumors. We will pursue various other novel targets with an autologous approach.
A truly scalable technology for automating cell therapy manufacturing.
Given the current challenges of existing autologous therapies, we have entered a risk-sharing collaboration with Lonza to use their Cocoon™ Manufacturing System. It effectively bypasses many of the industry-standard manual steps in product production by streamlining sample processing.
We believe the Cocoon will enable us to deliver a high-quality TAC101-Claudin 18.2 cell therapy product for each patient in need.
- Improved Quality and Reproducibility
- Decreased Footprint for Manufacturing at Scale
- Decreased Cost of Goods
- Broad Geographical Distribution
